Cartesian Therapeutics, Inc. (RNAC)

Cartesian Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	76.91	106.44	114.06	138.69	90.17
Short-Term Investments	0	28.16	14	0	0
Cash & Cash Equivalents	76.91	134.6	128.06	138.69	90.17
Cash Growth	-42.86%	5.11%	-7.66%	53.80%	141.08%
Receivables	8.85	9.76	9.91	7.22	5
Other Current Assets	4.97	3.78	6.47	5.43	1.5
Total Current Assets	90.73	148.14	144.44	151.34	96.67
Property, Plant & Equipment	12.18	14.41	11.97	12.34	1.52
Long-Term Investments	3.38	3.31	3.38	1.38	1.38
Goodwill and Intangibles	48.16	0	0	0	0
Other Long-Term Assets	150.6	0.03	0.09	0.37	0
Total Long-Term Assets	214.32	17.75	15.44	14.09	2.9
Total Assets	305.05	165.89	159.88	165.44	99.57
Accounts Payable	3.15	0.32	0.22	0.44	0.5
Deferred Revenue	5.85	0.59	65.3	110.8	16.35
Current Debt	2.17	10.08	7.01	0.91	19.28
Other Current Liabilities	57.04	14.08	-0.28	-30.6	-1.19
Total Current Liabilities	68.21	25.08	72.25	81.55	34.94
Long-Term Debt	8.79	27.84	28.27	34.44	0
Other Long-Term Liabilities	367.68	19.14	36.84	67.45	56.23
Total Long-Term Liabilities	376.47	46.98	65.11	101.89	56.23
Total Liabilities	444.68	72.06	137.36	183.44	91.17
Total Debt	10.96	37.93	35.28	35.35	19.28
Debt Growth	-71.11%	7.49%	-0.19%	83.37%	-9.86%
Retained Earnings	-614.65	-394.94	-430.32	-404.63	-335.75
Comprehensive Income	-4.6	-4.56	-4.57	-4.56	-4.52
Shareholders' Equity	-440.18	93.83	22.52	-18.01	8.4
Net Cash / Debt	65.96	96.68	92.77	103.34	70.9
Net Cash / Debt Growth	-31.78%	4.21%	-10.22%	45.76%	342.60%
Net Cash Per Share	12.76	19.88	24.34	30.63	46.69
Working Capital	22.52	123.06	72.19	69.8	61.72
Book Value Per Share	-85.14	19.45	5.91	-5.34	5.53

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).